1. Introduction {#s0005}
===============

Anticoagulants are effective medications for the treatment and prevention of thromboembolic disorders. These anticoagulants work by maintaining the international normalized ratio (INR), a measure of thrombotic status, within the therapeutic range. Indeed, several studies have shown that the higher the INR, the greater the risk of hemorrhage, while a lower INR is associated with increased risk of thromboembolism or stroke ([@b0045]). Although warfarin is the most commonly used anticoagulant in patients with stroke, the use of this drug is complicated by the wide interindividual variability in response and the dose required to achieve the target INR. This variability may be explained in part by age, use of concomitant medications, dietary vitamin K intake, impaired liver function, and heart failure ([@b0045], [@b0030], [@b0125]; and [@b0005]) as well as individual genetic variability ([@b0040], [@b0080], [@b0120]).

Polymorphisms of the *CYP2C9* gene, which encodes warfarin's major metabolizing enzyme, have been extensively studied. Genetic polymorphisms in *CYP2C9* alter its catalytic activity; rs1799853 and rs1057910 variants decrease enzyme activity ([@b0070]). Several studies have demonstrated that, an association between patients carrying of at least one of the rs1057910 or rs1799853 variant alleles and reduced warfarin doses, delayed stabilization of warfarin and a risk of major bleeding ([@b0040], [@b0015]; and [@b0095]).

The vitamin K epoxide reductase (VKOR) enzyme plays a significant role in the clotting pathway via the reduction of vitamin K-2,3 epoxide to vitamin K-hydroquinone, the latter of which is biologically active and enhances the production of clotting factors II, VII, IX and X. Warfarin inhibits VKOR activity by inhibiting the activity of subunit 1 of the vitamin K epoxide reductase complex (VKORC1) encoded by the *VKORC1* gene ([@b0055], [@b0080]). Several studies have found an association between the presence of *VKORC1* gene polymorphisms and a reduced dose of warfarin. Most of these studies demonstrated that *VKORC1* polymorphisms accounted for most of the variation in warfarin dose requirements compared to its *CYP2C9* counterpart ([@b0120], [@b0130]; and [@b0090]).

In order to keep warfarin therapy efficient and safe, the INR must remain within the target range (i.e., the therapeutic range of about 2--3). Therefore, the dosage must be adapted to the INR. At the initial phase of therapy, the warfarin dose is prescribed by the physician using the trial and error method and based on patients' clinical factors to obtain the therapeutic INR. While during the stabilization phase of therapy, the patients reached the target INR of at least two consecutive visits ([@b0020], [@b0050]). Therefore, the objective of this study was to evaluate the effects of *CYP2C9* and *VKORC1* polymorphisms on warfarin dose requirements during the stabilization phase of therapy in the Jordanian population.

2. Material and methods {#s0010}
=======================

2.1. Study design and patients {#s0015}
------------------------------

The study population consisted of 139 unrelated warfarin patients recruited from the Queen Alia Heart Institute (QAHI) anticoagulation clinic in Amman, Jordan. We included patients who started their therapy between January 2014 to November 2015. The inclusion criteria included 18 years or older, warfarin intake patients for at least 3 months and visit the anticoagulation clinic regularly. We excluded patients who have lost clinical data or patients with pharmacokinetics interacting drugs from the analysis during the follow-up period. These drugs have been identified according to Dutch standards for the treatment of coumarin interactions ([@b0105]). This study was approved by the human ethics committees with ethical code number 13/78/2014 at Jordan University of Science and Technology. All patients who met the inclusion criteria were informed about the objectives of the study and asked for their written consent.

Initially, 350 patients were examined, 300 of which were referred for participation in this study. 80 patients were subsequently excluded based on inclusion and exclusion criteria. Of the remaining patients, 220 agreed to participate in this study. Thereafter, eight more patients were excluded from the final analysis due to failure of genotyping (our method failed to determine the genotype of these patients due to low DNA content or degradation of DNA samples). Of these 212 patients, only 139 patients achieved the stabilization phase of therapy. Therefore, all data were obtained from 139 patients with cardiovascular disease who were treated with warfarin. The study design summarized in [Fig. 1](#f0005){ref-type="fig"}.Fig. 1Flow chart depicting study design. INR: international normalized ratio.

2.2. Data collection and follow-up time {#s0020}
---------------------------------------

Data was collected on a number of demographic characteristics such as gender, age, body mass index, smoking, and eating habits. Information was also collected on patient characteristics, including anticoagulant indication, appropriate therapeutic range of INR, INR measurements, warfarin dose, co-morbidity, co-medications, hemorrhage and lipid profile (e.g. cholesterol, low density lipoprotein (LDL), and high density lipoprotein (HDL)).

2.3. SNP selection and genotyping {#s0025}
---------------------------------

Candidate SNPs associated with warfarin metabolism or warfarin targets were obtained from a public database such as the SNP database of the National Center for Biotechnology Information ([@b0075]) (<http://www.ncbi.nlm.nih.gov/SNP/>) and the [@b0115] (<http://www.appliedbiosystems>). We selected 17 SNPs in the *CYP2C9* and *VKORC1* genes. Table S1 lists the genes, their SNP IDs, and their loci. After DNA extraction using the Wizard Genomic DNA Purification Kit (Promega), samples that met the quantitative requirements for this study were shipped to the Australian Genome Research Facility (AGRF) to determine genotype using the MassARRAY® System (iPLEX GOLD) (Sequenom, San Diego, CA, USA). The MassARRAY™ system protocol and the primers information used for the *CYP2C9* and *VKORC1* genes are available upon request.

2.4. Outcome measure {#s0030}
--------------------

The primary point of our study was based on evaluation of the sensitivity to warfarin during the stabilization phase of therapy. Therefore, patients were divided into the following three groups based on [@b0035] study:1.Extensive metabolizer or warfarin resistance group (high dose required \> 49 mg/week)2.Moderate metabolizer or warfarin response group (average dose required between 21 and 49 mg/week)3.Poor metabolizer group or warfarin-sensitive group (minimum required dose \< 21 mg/week).

The secondary point of the study was focused on warfarin responsiveness during the stabilization phase of therapy. Therefore, patients were classified according to [@b0040] study into:1.Good responders who have an INR value in the target range (therapeutic range)2.Poor responders (INR value below target)3.Ultra responders (INR over target)

Finally, the maintenance dose was defined as the average of all doses administered to a patient during stable anticoagulation. The stable maintenance dose was calculated from all weekly doses that remained unchanged for at least two consecutive visits under therapeutic INR.

2.5. Statistical analysis {#s0035}
-------------------------

The minor allele frequency (MAF) and the Hardy-Weinberg equilibrium (HWE) p-values were calculated. The Pearson χ2 test was used to evaluate the deviation of the HWE. Various genetic association analyses (Chi-square test, non-parametric correlation Kruskal Wallis test, unidirectional analysis of variance, and Tukey HSD post hoc multiple comparison test) were also performed to test which of the selected SNPs are associated with warfarin response. The Statistical Package for the Social Sciences (SPSS) version 21.0 was used for all statistical analyses.

3. Results {#s0040}
==========

A total of 139 patients met the criteria of our study. The demographic and clinical characteristics, mean dose and INR values from the first visits to the clinic and after achieving stabilization were collected and summarized in [Table 1](#t0005){ref-type="table"}. Ten of the 17 selected SNPs were not polymorphic, and only seven SNPs were included in this study, the latter of which passed quality control tests with high accuracy and low discrepancy rate. Genotypic and allelic frequencies for the 139 patients are summarized in Table S2.Table 1Analytical analysis of demographics and clinical characteristics of 139 cardiovascular patient treated with warfarin at the Queen Alia Heart Institute.CategorySubcategoryExtensive Metabolizer[a](#tblfn2){ref-type="table-fn"}Good Metabolizers[b](#tblfn3){ref-type="table-fn"}Poor Metabolizers[c](#tblfn4){ref-type="table-fn"}P value[\*](#tblfn1){ref-type="table-fn"}DemographicsPatients (N, %)(25/139) 18.0%(88/139) 63.3%(26/139) 18.7%Age[d](#tblfn5){ref-type="table-fn"} \[years\]47.6 \[17.7\]53.2 \[15.3\]54.2 \[18.4\]0.457BMI[d](#tblfn5){ref-type="table-fn"}26.7 \[4.0\]27.6 \[4.8\]28.0 \[6.6\]0.641Smoking (%)(12/25) 48.0%(18/88) 31.8%(12/26) 46.2%0.043Male(17/25) 68.0%(49/88) 55.7%(17/26) 65.4%0.304Female(8/25) 32.0%(39/88) 44.3%(9/26) 34.6%  Concomitant DiseaseCo morbidity(15/25) 60.0%(54/88) 61.4%(13/26) 50.0%0.578Hypertension(6/25) 24.0%(35/88) 39.8%(10/26) 38.5%0.425Diabetes mellitus(9/25) 36.0%(16/88) 18.2%(6/26) 23.1%0.124CHD[e](#tblfn6){ref-type="table-fn"}(8/25) 32.0%(17/88) 19.3%(6/26) 23.1%0.329Thyroid(1/25) 4.0%(2/88) 2.3%(0/26) 0.0%0.596Lipid(1/25) 4.0%(7/88) 8.0%(1/26) 3.8%0.673  MedicationAspirin(18/25) 72.0%(57/88) 64.8%(17/26) 65.4%0.600  Indication of TreatmentMVR[f](#tblfn7){ref-type="table-fn"}(5/25) 20.0%(9/88) 10.3%(6/26) 23.1%0.127AVR[g](#tblfn8){ref-type="table-fn"}(7/25) 28.0%(31/88) 35.2%(2/26) 7.7%AF[h](#tblfn9){ref-type="table-fn"}(6/25) 24.0%(14/88) 15.9%(5/26) 19.2%DVR[i](#tblfn10){ref-type="table-fn"}(6/25) 24.0%(15/88) 17.0%(9/26) 34.6%Others(1/25) 4.0%(19/88) 21.6%(4/26) 15.4%  Target INR2--3(10/25) 40.0%(37/88) 42.0%(11/26) 42.3%0.9982.5--3.5(15/25) 60.0%(51/88) 58.0%(15/26) 57.7%  Mean INR[d](#tblfn5){ref-type="table-fn"}2.4 \[0.53\]2.6 \[0.64\]2.9 \[0.56\]0.021[^1][^2][^3][^4][^5][^6][^7][^8][^9][^10]

3.1. Association of SNPs with warfarin sensitivity {#s0045}
--------------------------------------------------

Significant association was found between all four *VKORC1* SNPs and sensitivity to warfarin (p \< 0.001). Two of the *CYP2C9* SNPs, rs4086116 (P = 0.007) and rs1057910 (P \< 0.001), were also found to be significantly associated with warfarin sensitivity.

In fact, carriers of the *VKORC1* polymorphism rs10871454 (TT) had a significantly higher risk (33.3%) of being sensitive to warfarin compared to wild-type (CC) subjects (3.6%) or carriers of only one polymorphism (CT) (7.2%) ([Table 2](#t0010){ref-type="table"}). Moreover, carriers of the *CYP2C9* rs1057910 (AC) polymorphism had a significantly higher risk (32.3%) of being sensitive to warfarin (over-anticoagulation) compared with carriers of (AA) polymorphism (10.2%) ([Table 2](#t0010){ref-type="table"}). However, only the *CYP2C9* rs1799853 SNP showed no significant differences among the three warfarin-sensitive groups (Sensitive, moderate, resistant) (P = 0.654) ([Table 2](#t0010){ref-type="table"}).Table 2Association of *VKORC1* and *CYP2C9* SNPs with Warfarin Sensitivity during the Stabilization Phase of Therapy of 139 Cardiovascular Patients Treated with Warfarin.GeneSNP IDGenotypeSensitive[a](#tblfn12){ref-type="table-fn"}Moderate[b](#tblfn13){ref-type="table-fn"}Resistance[c](#tblfn14){ref-type="table-fn"}P-value[\*](#tblfn11){ref-type="table-fn"}*VKORC1*rs10871454CC(1/28) 3.6%(10/28) 35.7%(17/28) 60.7%\<0.001CT(5/69) 7.2%(51/69) 73.9%(13/69) 18.8%TT(14/42) 33.3%(25/42) 59.5%(3/42) 7.1%rs8050894CC(1/26) 3.8%(9/26) 34.6%(16/26) 61.5%\<0.001CG(5/69) 7.2%(50/69) 72.5%(14/69) 20.3%GG(14/44) 31.8%(27/44) 61.4%(3/44) 6.8%rs9934438CC(2/28) 7.2%(10/28) 35.7%(16/28) 57.1%\<0.001CT(5/71) 7.0%(53/71) 74.6%(13/71) 18.3%TT(14/40) 35.0%(23/40) 57.5%(3/40) 7.5%rs17708472CC(20/106) 18.8%(68/106) 64.2%(18/106) 17.0%0.003CT(1/30) 3.3%(17/30) 56.7%(12/30) 40.0%TT(1/3) 33.3%(0/3) 0.0%(2/3) 66.7%  *CYP2C9*rs1799853CC(14/105) 13.3%(65/105) 61.9%(26/105) 24.8%0.654CT(7/32) 21.9%(18/32) 56.2%(7/32) 21.9%TT(0/2) 0.0%(2/2) 100.0%(0/2) 0.0%rs4086116CC(6/77) 7.8%(46/77) 59.7%(25/77) 32.5%0.007CT(13/53) 24.5%(32/53) 60.4%(8/53) 15.1%TT(2/9) 22.2%(7/9) 77.8%(0/9) 0.0%rs1057910AA(11/108) 10.2%(66/108) 61.1%(31/108) 28.7%0.001AC(10/31) 32.3%(20/31) 64.5%(1/31) 3.2%[^11][^12][^13][^14]

3.2. Impact of VKORC1 and CYP2C9 SNPs on dose requirements {#s0050}
----------------------------------------------------------

Significant effect was observed when compared the doses collected at the beginning of the treatment with the doses after reaching the stabilization phase of the therapy, P \< 0.0001, except rs1799853 *CYP2C9* polymorphism ([Table 3](#t0015){ref-type="table"}).Table 3Association of *VKORC1* and *CYP2C9* SNPs with variability on warfarin required doses.GeneSNP IDGenotypeInitiation doseP-value [\*](#tblfn15){ref-type="table-fn"}Maintenance doseP-value[\*](#tblfn15){ref-type="table-fn"}*VKORC1*rs10871454CC51.35 \[15.55\]\<0.000153.02 \[18.02\]\<0.0001CT35.33 \[14.42\]39.48 \[17.06\]TT26.56 \[10.89\]27.41 \[10.33\]rs8050894CC51.84 \[15.32\]\<0.000153.06 \[18.39\]\<0.0001CG35.76 \[14.8139.96 \[17.33\]GG26.73 \[10.58\]27.80 \[10.22\]rs9934438CC51.35 \[15.55\]\<0.000153.02 \[18.02\]\<0.0001CT35.56 \[14.28\]39.47 \[16.83\]TT25.72 \[10.46\]26.82 \[10.19\]rs17708472CC33.67 \[15.68\]0.01236.37 \[18.13\]0.003CT41.64 \[15.53\]44.20 \[15.04\]TT57.80 \[8.08\]59.63 \[9.79\]  *CYP2C9*rs1799853CC37.22 \[16.37\]0.15440.00 \[18.30\]0.189CT32.54 \[15.11\]34.68 \[16.23\]TT21.25 \[0.354\]25.00 \[0.00\]rs4086116CC40.61 \[16.81\]0.000243.86 \[19.10\]0.0002CT30.90 \[13.38\]32.55 \[14.39\]TT25.23 \[11.56\]28.57 \[8.76\]rs1057910AA39.06 \[16.32\]\<0.000141.75 \[18.48\]\<0.0001AC24.95 \[9.34\]27.43 \[9.29\][^15]

3.3. Association of VKORC1 and CYP2C9 SNPs with warfarin responsiveness {#s0055}
-----------------------------------------------------------------------

Patients were divided into three groups (Poor-, good-, and ultra-responders). No significant differences were found between the investigated SNPs of *VKORC1* and *CYP2C9* ([Table 4](#t0020){ref-type="table"}).Table 4Association of *VKORC1* and *CYP2C9* SNPs with warfarin response during the stabilization phase of therapy of 139 cardiovascular patients treated with warfarin.GeneSNP IDGenotypePoor responder[a](#tblfn17){ref-type="table-fn"}Good responder[b](#tblfn18){ref-type="table-fn"}Ultra responder[c](#tblfn19){ref-type="table-fn"}P*-*value[\*](#tblfn16){ref-type="table-fn"}*VKORC1*rs10871454CC(0/28) 0.0%(27/28) 96.4%(1/28) 3.6%0.621CT(6/69) 8.7%(60/69) 87.0%(3/69) 4.3%TT(3/42) 7.1%(37/42) 88.1%(2/42) 4.8%rs8050894CC(0/26) 0.0%(25/26) 96.2%(1/26) 3.8%0.659CG(6/69) 8.7%(60/69) 87%(3/69) 4.3%GG(3/44) 6.8%(39/44) 88.6%(2/44) 4.5%rs9934438CC(0/28) 0.0%(27/28) 96.4%(1/28) 3.6%0.527CT(6/71) 8.6%(61/71) 85.9%(4/71) 5.5%TT(3/40) 7.5%(36/40) 90.0%(1/40) 2.5%rs17708472CC(6/106) 5.7%(94/106) 88.7%(6/106) 5.6%0.593CT(3/30) 10.0%(27/30) 90.0%(0/0) 0.0%TT(0/3) 0.0%(3/3) 100.0%0.0%  *CYP2C9*rs1799853CC(8/105) 7.6%(93/105) 88.6%(4/105) 3.8%0.851CT(1/32) 3.1%(29/32) 90.6%(2/32) 6.3%TT(0.0) 0.0%(2/2) 100.0%0.0%rs4086116CC(6/77) 7.8%(68/77) 88.3%(3/77) 3.9%0.806CT(3/53) 5.7%(47/53) 88.6%(3/53) 5.7%TT(0/9) 0.0%(9/9) 100.0%0.0%rs1057910AA(8/108) 7.4%(94/108) 87.0%(6/108) 5.6%0.269AC(1/31) 3.2%(30/31) 96.8%0.0%[^16][^17][^18][^19]

3.4. Impact of VKORC1 and CYP2C9 SNPs on INR values {#s0060}
---------------------------------------------------

No significant associations were observed when compared the INR values were measure at the beginning of treatments and the INR values measured after reaching the stabilization phase of the therapy ([Table 5](#t0025){ref-type="table"}).Table 5Association of *VKORC1* and *CYP2C9* SNPs with INR Treatment Outcome.GeneSNP IDGenotypeInitiation INRP-value[\*](#tblfn20){ref-type="table-fn"}Maintenance INRP-value[\*](#tblfn20){ref-type="table-fn"}*VKORC1*rs10871454CC2.73 \[0.58\]0.3462.63 \[0.40\]0.297CT2.60 \[0.40\]2.68 \[0.63\]TT2.54 \[0.65\]2.74 \[0.36\]rs8050894CC2.71 \[0.58\]0.3622.63 \[0.39\]0.246CG2.63 \[0.67\]2.67 \[0.39\]GG2.52 \[0.58\]2.77 \[0.38\]rs9934438CC2.73 \[0.58\]0.2532.63 \[0.40\]0.312CT2.61 \[0.67\]2.68 \[0.40\]TT2.51 \[0.57\]2.76 \[0.36\]rs17708472CC2.59 \[0.67\]0.9012.71 \[0.41\]0.517CT2.67 \[0.45\]2.64 \[0.33\]TT2.53 \[0.50\]2.50 \[0.17\]  *CYP2C9*rs1799853CC2.51 \[0.61\]0.1592.69 \[0.38\]0.381CT2.63 \[0.69\]2.69 \[0.42\]TT3.20 \[0.14\]3.00 \[0.0\]rs4086116CC2.67 \[0.61\]0.6212.67 \[0.40\]0.389CT2.54 \[0.63\]2.70 \[0.37\]TT2.49 \[0.73\]2.83 \[0.43\]rs1057910AA2.66 \[0.66\]0.0462.67 \[0.40\]0.190AC2.41 \[0.46\]2.77 \[0.35\][^20]

4. Discussion {#s0065}
=============

The results of our study, which examined the role of the *CYP2C9* and *VKORC1* polymorphisms in warfarin response and sensitivity in cardiovascular patients during the stabilization phase of therapy, strongly suggest an association between certain *CYP2C9* and *VKORC1* variant alleles and sensitivity to warfarin. However, no such correlation was found between the *VKORC1* and *CYP2C9* polymorphisms and warfarin response and INR measurements.

The findings of the current research are consistent with previous studies. For example, the allelic frequency of the *CYP2C9* (rs1799853) T allele (12.9%) was found at similar levels for Jordanians ([@b0135]), Americans and Europeans ([@b0025]). While, the *CYP2C9* (rs1057910) C allele (11.2%) was more common in our study than [@b0135] study with 6.8% frequency, and more than Americans (6%), Europeans (6%), Asians (4%) and Africans (1%) frequencies ([@b0025]). Moreover, the allelic frequency of the rs10871454 T allele of *VKORC1* is 55% and is drastically different from those found in the African (6%) and East-Asian (89%) populations. Similarly, the allelic frequency of the rs8050894C allele of *VKORC1* in our population (43.5%) is also different from the African (74%) and East-Asian (12%) populations ([@b0025]).

[@b0110] reported that *CYP2C9* polymorphisms rs1799853 and rs1057910 decrease the rates of warfarin clearance, reducing its activity will lead to a lower required dose, therefore, increase warfarin sensitivity risk ([@b0110]). In accordance with that, we found a significant association between rs1057910 (A \> C) and sensitivity to warfarin during the stabilization phase of therapy (P = 0.001). In fact, 32% of CA carriers and only 10% of the wild-type carriers were sensitive to warfarin, meaning that patients with this variant require lower doses than the wild-type ([Table 2](#t0010){ref-type="table"}). In addition, the *CYP2C9* variant (rs4086116 C \> T) also showed a significant association with warfarin sensitivity during the stabilization phase (P = 0.007) ([Table 2](#t0010){ref-type="table"}). Therefore, patients carrying this variant require lower warfarin doses than wild-type carriers. Although numerous studies have reported that patients who carry one rs1799853 allele results in a dose reduction of 6--45% compared with the wild type dose ([@b0040], [@b0060]), our results showed no significant association between *CYP2C9* rs1799853 and warfarin sensitivity (P = 0.654). This could be explained by the impact of genotypic frequency on the genetic associations, since in this study of the 139 patients there were only two patients who are homozygous for the variant allele and 105 patients who are homozygous for wild-type allele ([Table 2](#t0010){ref-type="table"}). Additionally, [@b0065], [@b0100] found an association between rs8050894 (1542G \> C) and rs1057910 *CYP2C9* SNPs and with a low warfarin dose in European American and Sudanese patients, respectively ([@b0065], [@b0100]). Our findings exhibit a significant association between rs1057910 and rs8050894 SNPs and variation in warfarin required dose with a 34.9% reduction in maintenance dose for carriers of homozygous variant allele TT of rs4086116 with P = 0.0002 ([Table 3](#t0015){ref-type="table"}).

Moreover, the *VKORC1* rs9934438 SNP was particularly associated with the low-dose warfarin phenotype, causing patients with this SNP to be classified as warfarin-sensitive patients ([@b0010]). Accordingly, our results show that 33% of patients carrying homozygous variants are more sensitive to warfarin than wild-type carriers (9.7%) ([Table 2](#t0010){ref-type="table"}). Furthermore, [@b0085], [@b0130] reported that patients with the *VKORC1* rs9934438 (1173T) allele had a lower dose of warfarin (average dose of 25 mg/week) compared with carriers wild type (35 mg/week) ([@b0085], [@b0130]). Accordingly, our study showed that patients with the homozygous to T allele had an average dose of 26.82 mg/week and carriers of wild type CC an average dose of 53.02 mg/week (P \< 0.0001).

During the stabilization phase of therapy, patients carrying different *CYP2C9* genotypes were not significantly distributed through the different responder groups. For example, 87% of patients carrying the *CYP2C9* rs1057910 wild-type allele CC were good responders, 7.4% were poor responders, and 5.6% were ultra-responders, while 96.8% of CT heterozygote carrier were good responders and 3.2% were poor responders (p = 0.269) ([Table 4](#t0020){ref-type="table"}). [@b0085] reported that, although, genotypic and allelic variants affected warfarin sensitivity and causing lower warfarin required dose, once a stable anticoagulation is established in patients, their response is constant and they are no longer having a risk of over anticoagulation ([@b0085]). In accordance with previous research, our results show that patients carrying different *VKORC1* genotypes were not significantly associated with warfarin responsiveness during the stabilization phase of therapy. For example, 88.7% of patients having the *VKORC1* rs17708472 wild type allele (CC) were good responders and 5.7% of them were poor responders. On a similar note, 90% of CT heterozygote carriers were good responders and 10.0% were poor responders (P = 0.593) ([Table 4](#t0020){ref-type="table"}).

When we compared the measurement of INR values in the first weeks of treatment and when patients reached the stabilization phase and then investigated the influence of different alleles of *CYP2C9* and *VKORC1* on the average INR, no significant differences were observed in all SNPs studied. Therefore, the *CYP2C9* and *VKORC1* polymorphisms are not associated with the development of a high or low INR in Jordanian cardiovascular patient ([Table 5](#t0025){ref-type="table"}).

5. Conclusion {#s0070}
=============

In the present study, we examined the incidence of *CYP2C9* and *VKORC1* polymorphisms in our population and then investigated whether they have an effect on warfarin sensitivity and responsiveness during the stabilization phase of therapy. Conclusively, our study indicates that the presence of *VKORC1* or *CYP2C9* polymorphisms is associated with sensitivity to warfarin during the stabilization phase. Moreover, being a *VKORC1* or *CYP2C9* polymorphism carrier is associated with a variation in the warfarin dose required to achieve a therapeutic INR compared to that required in wild-type patients. While, these variants lack associated with the responsiveness to warfarin and the outcome measure of INR in our population. In order to confirm our findings, further studies with larger sample sizes are required in addition to investigating the combined effect of these SNPs on the sensitivity and responsiveness of warfarin. Finally, expanded pharmacogenetic study is required to evaluate the effects of other clinical and genetic factors (such as the coagulation factors and metabolizing warfarin genes) on warfarin sensitivity and responsiveness during the stabilization phase of therapy and their effects on adverse drug events.
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[^1]: P value \< 0.05 is considered significant.

[^2]: Extensive metabloizer or warfarin resistance group (required high warfarin dose \> 49 mg/week).

[^3]: Moderate metabolizer or warfarin response group (required average warfarin dose between 21 and 49 mg/week).

[^4]: Poor metabolizer group or warfarin-sensitive group (required minimum warfarin dose \< 21 mg/week).

[^5]: Mean Standard deviation in square brackets.

[^6]: CHD: Chronic heart disease.

[^7]: MVR:Mitral valve replacement.

[^8]: AVR: Aortic valve replacement.

[^9]: AF: Atrial Fibrillation.

[^10]: DVR: Double valve replacement.

[^11]: Chi-square test with p value \< 0.05 is considered significant.

[^12]: Warfarin Sensitive group (required minimum warfarin dose \< 21 mg/week).

[^13]: Warfarin Moderate response group (required average warfarin dose between 21 and 49 mg/week).

[^14]: Warfarin Resistance group (required high warfarin dose \> 49 mg/week).

[^15]: One-way ANOVA test with P-value \< 0.05 is considered significant, Mean Standard deviation in square brackets.

[^16]: Chi-Square Test with p value \< 0.05 is considered significant.

[^17]: Poor responders (INR value below target).

[^18]: Good responders who have an INR value in the target range (therapeutic range).

[^19]: Ultra responders (INR over target).

[^20]: One-way ANOVA test with p-value \< 0.05 is considered significant, Mean Standard deviation in square brackets.
